Introduction
T lymphocytes such as natural killer (NK) cells, lymphokine-activated killer (LAK) cells, tumorinfiltrating lymphocytes (TIL) and cytotoxic T lymphocytes (CTL) have been considered to be useful for adoptive immunotherapy of human tumors (Rosenberg et al., 1985; Sato et al., 1986; Rosenberg et al., 1988) . Lymphokine-activated killer (LAK) cells were once thought to be promising from animal experiments (Takahashi et al., 1993a; Takahashi et al., 1993b ), but were not so effective in clinical studies (Fisher et al., 1988; Rosenberg et al., 1987) .
Cytotoxic T lymphocytes (CTL) have higher cytotoxicity (Miyatake et al., 1988) than LAK cells on specific tumors that have been used as antigen-like stimulators during induction of lymphocyte proliferation. If autologous CTL could be generated, they should be better than LAK and TIL for adoptive immunotherapy (Crowley et al., 1991; Wolfel et al., 1993) since CTL are known to kill tumor cells more efficiently than LAK and TIL (Slingluff et al., 1994) . This led us to expect that CTL might be useful clinically for adoptive immunotherapy of tumors.
There are many reports of establishment and characterization of tumor-specific murine CTL lines and possible therapeutic effects of CTL (Ibayashi et al., 1985; Kedar et al., 1984; Plata, 1982; Ryser et al., 1978; Yamasaki et al., 1984) . However, although human autologous CTL are required for clinical treatment of tumors, induction of human CTL is not easy. As Gillis et al. (1979) succeeded in induction of murine CTL, De Vries and Spits (1984) used a similar mixed lymphocyte reaction for initial activation of human lymphocytes. Abo and Balch (1982) , Mazumder et al. (1982 and 1983) , and Mukherji et al. (1989) tried continuous stimulation of lymphocytes with lectins together with inactivated target tumor cells. Nakashima et al. (1994) used tumor-involved lymphnodes as a source of candidate CTL and Rosenberg et al. (1986) cultured TIL as CTL.
However, practical barriers do exist for induction of CTL. First, stimulation of T lymphocyte with a sufficient amount of target tumor cells is essential to induce CTL in vitro, but primary culture and subsequent establishment of human tumor cell lines is generally timeconsuming, tedious processes and not practical for all patients (Hay et al., 1994) . Second, autologous CTL are the most suitable to avoid unnecessary side effects of lymphocyte reactions, but at present, routine induction of autologous CTL from lymphocytes is a hard technique except when the CTL are recruited from TIL (Rosenberg et al., 1986) , and the small pieces of tumors removed surgically are usually insufficient to yield a number of TIL. Therefore, induction of autologous CTL against small brain tumors from peripheral blood lymhocytes is usually unsuccessful except special cases (Letessier et al., 1991; Miyatake et al., 1988) .
In the present mini-review article, I will describe shortly on induction of CTL from peripheral blood mononuclear cells (PBMC), first on allogeneic established cell lines together with serum/plasma-free culture of the induced CTL, second on formalin-fixed paraffin-embedded specimens of the gastric cancer tissue, and third on autologous brain tumor tissue fragments. Finally, I will introduce recent technique to induce CTL on antigenic peptide-loaded cells.
Induction of allogeneic CTL against human lung cancer cells
To generate CTL from PBMC, we utilized the culture medium RHAM which has originally been developed for serum-free culture of human lymphocytes and applied to LAK cell culture supplemented with 5% plasma (Kawai, et al., 1992) . By combining this novel enriched medium supplemented with an interleukin cocktail of IL-1, -2, -4, and -6 (Nakashima et al., 1994) and 5% autologous plasma of the PBMC donor, we could induce reproducibly allogeneic CTL against the human lung squamous carcinoma cell line SQ-5 from PBMC of healthy volunteers (Liu et al., 1994) . Briefly, the PBMC were cocultured on X-ray irradiated live SQ-5 cells. This coculture resulted in detachment and killing of almost all SQ-5 cells within 5 days. After this induction period and subsequent subculture for 2 weeks, allogeneic CTL grown from the PBMC killed SQ-5 cells but not other human cell lines such as the lung squamous carcinoma cell line AOI, the lung adenocarcinoma cell line A549, the NK cell-sensitive cell line K562, and the LAK cell-sensitive cell line Daudi (Figure 1 ). The CTL (named SQ-5-CTL) could be routinely subcultured on unirradiated target SQ-5 cells at an E/T ratio of 10, since SQ-5 cells disappeared within 1 day after addition of the SQ-5-CTL. Phenotypic analysis by flow cytometry showed that the SQ-5-CTL culture contained 98% CD3 + , 95% CD8 + , and 5% CD4 + after cultured for over one month.
Serum/plasma-free culture of the allogeneic CTL
In typical cases of lung cancer, treatment with LAK cells required 10 10 -10 11 effector cells for treatment of one patient, indicating that 10-30 liter-scale culture (cell concentration: 10 6 -3 10 6 ml 1 ) is necessary, with use of 1-3 liters of human serum. Considering the difficulties in safe and efficient preparation, continuous low cost supply, and relatively complicated handling of human serum or plasma, serum/plasma-free culture of CTL seems desirable. The dependencies of CTL growth on serum/plasma and target cells were tested in the RHAM medium containing the IL-cocktail (Liu et al., 1994) .
Growth of SQ-5-CTL depended on target cell supplementation at each subculture at 5 day intervals, without autologous plasma, when human serum albumin (HSA) was added at 0.5%. During the first 5 day period of subcuture, the number of CTL increased 4.4-fold in medium with 5% autologous plasma and 3-fold in medium with 0.5% HSA. After initial induction of CTL for 5 days, long-term serum/plasma-free culture was carried out with bovine serum albumin (BSA). During 6 subcultures after the 5-day induction culture, the mean doubling times of CTL were 40 and 50 h in media containing plasma and BSA, respectively. Although CTL grew less in BSA medium than in plasma medium, the cumulative number of CTL cultured in serum/plasma-free conditions reached 10 11 in 35 days.
Induction of CTL on live and formalin-fixed paraffin-embedded gastric cancer cells
If possible, more stable sources of the tumor-specific antigen are desirable than established cell lines or operationally removed fresh tumor tissues for induction of CTL. After removal of tumor tissues by operation, formalin-fixed paraffin-embedded blocks of the tissue are always prepared and stored for subsequent diag-nosis. As formalin fixation preserves the specific antigenicity of tumor cells (Pollard and Holgate, 1987) , these preparations should be an alternative source for CTL induction. After established a cancer cell line, we tried to generate CTL from peripheral blood on both the live target cells and the corresponding fixed paraffin-embedded sections (Liu et al., 1995) . The gastric adenocarcinoma cell line GT3TKB was established by extensive passage of cells in ascites of a 53-year-old patient. Based on reported techniques for CTL generation (Crowley et al., 1991; Wolfel et al., 1993; Liu et al., 1994) , selective growth of the CTL was observed on repeated stimulation of PBMC with X-ray-irradiated live GT3TKB [ Figure 2 , defined as CTL(live)].
Paraffin-embedded thin sections of the original gastric mucosa containing the cancer and surrounding normal mucosal tissue were washed sequentially with toluene and ethanol. They were then added to PBMC in culture medium RHAM containing 5% autologous plasma and the IL-cocktail. Microscopic examination showed that the lymphocytes that attached to the tissue sections grew as aggregates, while most of the unattached lymphocytes died within the first 2 weeks. Once the cells began to grow [ Figure 2 , defined as CTL(fix), the lag phase of growth of CTL(fix) was 4 times that of CTL(live) in the induction culture], the two types of CTL showed almost the same cumulative growth curves when they entered the log-phase. As the sections gradually became fragmented and disappeared during dilution culture of the lymphocytes and further sections were not added, the growth of CTL(fix) rapidly slowed down after 56 days. But on use of a culture surface precoated with anti-CD3 monoclonal antibody for stimulation, CTL(fix) continued to grow as in the presence of cancerous tissue sections (Figure 2 , dotted line) for 4 months.
Both types of CTL showed strong killing activity on live target GT3TKB cells assayed by staining with crystal violet (CV) after removal of the non-adherent effector lymphocytes (Saotome et al., 1989) . CTL(live) and CTL(fix) killed over 85% of the GT3TKB cells in 24 h at an effector/target (E/T) ratio of 1. On incubation for 24 h at this low E/T ratio, LAK and NK did not kill GT3TKB cells efficiently.
In 48 h incubation for specificity assay, CTL(fix) showed highly specific killing activity of the GT3TKB cells, but not of the other gastric tumor cell line GCIY, normal kidney cells HPT12N, or NK-sensitive K562 cells. They caused partial killing of LAK-sensitive Daudi cells. These activities were almost the same as those of CTL(live). Phenotype analyses by flow cytometry indicated that both types of CTL were CD3 + CD16 CD8 + , while LAK were a mixture of CD4 + cells (28.1%) and CD8 + cells (34.0%). We confirmed that the target GT3TKB cells were expressing MHC-class I molecules on their surface by cytofluorometry.
Induction of autologous CTL against brain tumor cells
We tried to induce autologous CTL from PBMC by coculture directly on minced tissue fragments of glioblastoma multiforme (GM) (Tsurushima et al., 1996) , since in a common primary culture medium, DMEM containing 10% FBS, human GM cells from the patient did not proliferate, although small numbers of astrocytelike cells and fibroblasts grew out from the tumor fragments for at most 5-7 days. Since reported CTLs are usually restricted by major histocompatibility complex (MHC) class I molecules expressed on the target cell surface (Roberts et al., 1987; Crowley et al., 1991) and the MHC class I molecules are known to be induced with interferon-(IFN) (Heron et al., 1978; Wallach et al., 1982; Carrel et al., 1985) we also added human IFN to the medium for the first 4 days. After this period, IFN was omitted from the culture medium. As a control, LAK cells were also induced from the same PBMC by the method reported previously . After cultured for 14 days, the CTL (CTL-IFN) killed almost all tumor cells at an E/T ratio of 1.67 on 48 h incubation (Figure 3) . The CTL induced Both of CTL and CTL-IFN had similar cytotoxicity on allogeneic GM cell line U87-MG to LAK cells and no substantial cytotoxicity on allogeneic GM cell line KG-1-C co-cultured for 24 h at higher E/T ratios. Both of the CTLs showed no cytotoxicity against LAK-sensitive Daudi cells, NK-sensitive K562 cells or autologous fibroblasts outgrown from the brain tumor, although they showed slight cytotoxicities against allogeneic GM cell lines. These results suggest that human autologous CTL can be induced from PBMC depending on brain tumor fragments but not on established tumor cell lines or on long-term primary cultured tumor cells. These are advantageous to established cell lines as the target, since we could save time for long-term primary culture and the tumor cells are thought to be minimally deviated from their state in vivo. These findings should contribute to a simple method of CTL generation and subsequent adoptive immunotherapy of brain tumors.
Antigenic peptides for CTL induction
In a T-cell receptor-mediated and MHC-restricted manner, CTL recognize antigenic epitope (peptides) presented by MHC-class I molecules on the surface of target cells (reviewed by Knuth et al., 1992) . A number of peptides have been identified recognized by CTL/TIL against melanoma. These are octa-, nona-, or deca-peptides identified as a part of MAGE-1, -3 antigens (van der Bruggen et al., 1991; Gaugler et al., 1994) , melanocyte-specific tyrosinase (Brichard et al., 1993) , gp100 melanocyte specific protein (Bakker et al., 1994) , melanocyte differentiation antigen Melan A/MART-1 and gp75 (Coulie et al., 1994; Kawakami et al., 1995; Wang et al., 1995) . Although the original idea was derived from viral-encoded peptides eluted from MHC-class I molecules (Falk et al., 1991; Jardetzky et al., 1991) , researchers adapted a peptide stimulation strategy for the induction of a CTL response not only to synthetic viral peptides of influenza matrix protein (Gotch et al., 1987) and hepatitis B and C viruses (Cerny et al., 1995; Bertoletti et al., 1991) but also to MAGE-2 and -3 gene peptides (Celis et al., 1994) , HLA-A0201-binding tyrosinase peptide (Visseren et al., 1995) , and peptides from myelin basic protein, proteolipid protein, and myelin-associated glycoprotein (Tsuchida et al., 1994) .
However, for induction of CTL, the approach of peptide-loading on target cells requires repetitive longterm stimulation or a large quantity of the peptides for bulk cultures containing large numbers of naive PBMC (Cerny et al., 1995) . Successful activation of CTL is critically dependent on adequate presentation of the epitopes involved. Since dentritic cells express high levels of MHC-class I and II and costimulatory molecules, Ossevoort et al. (1995) demonstrated the effectiveness of highly purified spleen den-dritic cells that efficiently induce primary pepetidespecific CTL responses in vitro to human papilloma virus 16 E7(49-57) peptide. Independently, Bakker et al. (1995) also successfully generated anti-melanoma CTL from healthy donors after presentation of the epitope-peptides by dentritic cells in vitro. In the in vivo trials, cultured autologous antigen presenting cells pulsed with the synthetic nonapeptide of MAGE-1 gene product were capable of inducing autologous malanoma-reactive and the nonapeptide-specific CTLs in patients with advanced stage IV melanoma (Mukherji et al., 1995) .
Conclusion
Induction and large scale culture of specific CTL against tumor cells are important for adoptive immunotherapy. Tumor cell killing activity of the allogeneic SQ-5-CTL could be maintained for over a month without apparent decrease of target specificity in serum/plasma-free culture conditions. With an autologous set of PBMC and target tumor cells, it should also be possible to maintain autologous CTL under serum/plasma-free conditions once the CTL have been induced in the presence of serum or plasma and an appropriate interleukin cocktail.
Moreover, our study suggests that tumor-specific CTL can be generated from peripheral blood on formalin-fixed paraffin-embedded tumor tissue sections as on live tumor cells. On the culture on an anti-CD3 monoclonal antibody-coated surface, the cumulative number of CTL(fix) was calculated to reach over 6 10 13 for 121 days. This growth potency of the CTL implies that it is possible to treat a patient for more than 100 therapeutic courses.
Whenever we find epitope-peptides presented on the surface of tumor cells, successful induction of CTL responses with peptide-pulsed dendritic cells illustrates the potential use of antigen-presenting cells for vaccination protocols in human tumor.
